Cargando…

Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination

BACKGROUND: Severe side effects after vaccination with coronavirus disease 2019 (COVID‐19) vaccines are rare but can be fatal. To date, vaccine‐induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID‐19 vaccines. Here, we report...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosseinzadeh, Rezvan, Barary, Mohammad, Mehdinezhad, Hamed, Sio, Terence T., Langer, Florian, Khosravi, Sahar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210570/
https://www.ncbi.nlm.nih.gov/pubmed/35769629
http://dx.doi.org/10.1002/rth2.12750
_version_ 1784730185539518464
author Hosseinzadeh, Rezvan
Barary, Mohammad
Mehdinezhad, Hamed
Sio, Terence T.
Langer, Florian
Khosravi, Sahar
author_facet Hosseinzadeh, Rezvan
Barary, Mohammad
Mehdinezhad, Hamed
Sio, Terence T.
Langer, Florian
Khosravi, Sahar
author_sort Hosseinzadeh, Rezvan
collection PubMed
description BACKGROUND: Severe side effects after vaccination with coronavirus disease 2019 (COVID‐19) vaccines are rare but can be fatal. To date, vaccine‐induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID‐19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine. KEY CLINICAL QUESTION: The Key Clinical Question was to determine whether inactivated COVID‐19 vaccines could induce VITT and how to diagnose and treat such cases. CLINICAL APPROACH AND CONCLUSIONS: Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti‐heparin–platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high‐dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.
format Online
Article
Text
id pubmed-9210570
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92105702022-06-28 Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination Hosseinzadeh, Rezvan Barary, Mohammad Mehdinezhad, Hamed Sio, Terence T. Langer, Florian Khosravi, Sahar Res Pract Thromb Haemost Case Reports BACKGROUND: Severe side effects after vaccination with coronavirus disease 2019 (COVID‐19) vaccines are rare but can be fatal. To date, vaccine‐induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID‐19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine. KEY CLINICAL QUESTION: The Key Clinical Question was to determine whether inactivated COVID‐19 vaccines could induce VITT and how to diagnose and treat such cases. CLINICAL APPROACH AND CONCLUSIONS: Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti‐heparin–platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high‐dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant. John Wiley and Sons Inc. 2022-06-21 /pmc/articles/PMC9210570/ /pubmed/35769629 http://dx.doi.org/10.1002/rth2.12750 Text en © 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Hosseinzadeh, Rezvan
Barary, Mohammad
Mehdinezhad, Hamed
Sio, Terence T.
Langer, Florian
Khosravi, Sahar
Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
title Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
title_full Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
title_fullStr Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
title_full_unstemmed Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
title_short Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
title_sort thrombotic thrombocytopenia after sinopharm bbibp‐corv covid‐19 vaccination
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210570/
https://www.ncbi.nlm.nih.gov/pubmed/35769629
http://dx.doi.org/10.1002/rth2.12750
work_keys_str_mv AT hosseinzadehrezvan thromboticthrombocytopeniaaftersinopharmbbibpcorvcovid19vaccination
AT bararymohammad thromboticthrombocytopeniaaftersinopharmbbibpcorvcovid19vaccination
AT mehdinezhadhamed thromboticthrombocytopeniaaftersinopharmbbibpcorvcovid19vaccination
AT sioterencet thromboticthrombocytopeniaaftersinopharmbbibpcorvcovid19vaccination
AT langerflorian thromboticthrombocytopeniaaftersinopharmbbibpcorvcovid19vaccination
AT khosravisahar thromboticthrombocytopeniaaftersinopharmbbibpcorvcovid19vaccination